Literature DB >> 2891122

Lipophilicity, hydrophilicity, and the central nervous system side effects of beta blockers.

D E Drayer1.   

Abstract

One of the attributes of beta-adrenergic blocking agents that has distinguished these drugs from each other is degree of lipophilicity. While this feature may play a role in facilitating passage across the blood-brain barrier, it is essential to realize that crossing the barrier is not necessarily synonymous with the ability to cause central nervous system (CNS) effects. Several studies have found some degree of CNS side effects, particularly tiredness and fatigue, with atenolol, a hydrophilic beta blocker. Pindolol, a moderately lipophilic beta blocker, has been reported to cause greater disturbances on electroencephalogram (EEG) than propranolol, the most highly lipophilic beta blocker. The investigational agent bevantolol exhibits a moderate degree of lipophilicity and a low frequency of CNS side effects. Drug-induced increases in plasma catecholamine levels, the possible saturation of CNS receptor sites at relatively low drug levels, and the specific structural details of beta-blocker molecules have been suggested as possible contributory factors in determining the degree of CNS effects.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2891122     DOI: 10.1002/j.1875-9114.1987.tb04029.x

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  13 in total

1.  Instructional model to teach clinically relevant medicinal chemistry.

Authors:  Naser Z Alsharif; Kimberly A Galt; Ahmed Mehanna; Robert Chapman; Alaba M Ogunbadeniyi
Journal:  Am J Pharm Educ       Date:  2006-08-15       Impact factor: 2.047

2.  Exercise-induced pulmonary vasoconstriction during combined blockade of nitric oxide synthase and beta adrenergic receptors.

Authors:  D W Kane; T Tesauro; T Koizumi; R Gupta; J H Newman
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

3.  CNS-related subjective symptoms during treatment with beta 1-adrenoceptor antagonists (atenolol, metoprolol): two double-blind placebo controlled studies.

Authors:  E Dimenäs; C Dahlöf; B Olofsson; I Wiklund
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

Review 4.  Current Opinions and Consensus for Studying Tremor in Animal Models.

Authors:  Sheng-Han Kuo; Elan D Louis; Phyllis L Faust; Adrian Handforth; Su-Youne Chang; Billur Avlar; Eric J Lang; Ming-Kai Pan; Lauren N Miterko; Amanda M Brown; Roy V Sillitoe; Collin J Anderson; Stefan M Pulst; Martin J Gallagher; Kyle A Lyman; Dane M Chetkovich; Lorraine N Clark; Murni Tio; Eng-King Tan; Rodger J Elble
Journal:  Cerebellum       Date:  2019-12       Impact factor: 3.847

5.  Prediction of sleep disorders induced by beta-adrenergic receptor blocking agents based on receptor occupancy.

Authors:  Y Yamada; F Shibuya; J Hamada; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1995-04

Review 6.  Quality of life as a therapeutic end-point. An analysis of therapeutic trials in hypertension.

Authors:  N K Hollenberg; M Testa; G H Williams
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

7.  Atenolol offers better protection than clonidine against cardiac injury in kainic acid-induced status epilepticus.

Authors:  M I Read; J C Harrison; D S Kerr; I A Sammut
Journal:  Br J Pharmacol       Date:  2015-08-24       Impact factor: 8.739

8.  Comparative effectiveness of 2 β-blockers in hypertensive patients.

Authors:  Emily D Parker; Karen L Margolis; Nicole K Trower; David J Magid; Heather M Tavel; Susan M Shetterly; P Michael Ho; Bix E Swain; Patrick J O'Connor
Journal:  Arch Intern Med       Date:  2012-10-08

9.  Metoprolol-induced visual hallucinations: a case series.

Authors:  Jonathan A Goldner
Journal:  J Med Case Rep       Date:  2012-02-15

10.  Pharmacological Hypotension as a Cause of Delirious Mania in a Patient with Bipolar Disorder.

Authors:  Manuel Glauco Carbone; Mario Miniati; Marly Simoncini; Beniamino Tripodi; Claudia Tagliarini; Claudia Carmassi; Liliana Dell'Osso
Journal:  Case Rep Psychiatry       Date:  2017-12-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.